SIP
ANIP icon

Stoneridge Investment Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Stoneridge Investment Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,730
Closed -$482K – 258
2017
Q1 		$482K Buy
+9,730
New +$546K 0.07% 221

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Stoneridge Investment Partners's ANIP Position: Q2 2017 in Review

Stoneridge Investment Partners sold out of ANI Pharmaceuticals (ANIP) in Q2 2017, closing a stake of 9,730 shares — an estimated $482K sold.

Stoneridge Investment Partners first reported a position in ANIP in Q1 2017 and held it in 1 quarter. The position peaked at $482K in Q1 2017. 151 funds tracked by Wall St. Rank hold ANIP as of Q2 2017.

  • Stoneridge Investment Partners reported no remaining ANI Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 9,730 ANI Pharmaceuticals shares in Q2 2017, an estimated $482K.
  • Stoneridge Investment Partners first reported a position in ANI Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Stoneridge Investment Partners's ANI Pharmaceuticals position peaked at $482K in Q1 2017.
  • 151 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2017.

Based on Stoneridge Investment Partners's 13F filing for Q2 2017, filed 1 Aug 2017.